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Abstract 
Background: Chloroquine (CQ) continues to be the first-line medication used worldwide in the treatment of Plas-
modium vivax malaria. The dose recommended by the World Health Organization is 25 mg/kg independently of the 
age of the subject. Nonetheless, the pharmacokinetics and pharmacodynamics of drugs in children are different from 
those in adults and may influence the drug concentrations in blood and become risk factors for therapeutic failure 
and/o resistance to CQ.
Methods: This study is a secondary analysis of the data from a clinical trial in which children over 5 years of age 
were administered 25 mg/kg of CQ, and CQ concentrations in blood were measured at day 7 of follow-up. Models of 
regression and comparison were used to evaluate and compare the CQ dose taken per kg/body weight, the CQ dose 
calculated based on body surface area, CQ levels in blood on day 7 and the age of the population.
Results: The younger the study population the greater the difference between the dose per kg/body weight 
(real dose) and that calculated according to the BSA (theoretical dose). The difference between the two doses was 
−181.206 mg in the 5–9 years of age group (CI 95 % −195.39; −167.02 mg) and −71.39 mg (CI 95 % −118.61; 
−23.99 mg) in the 10–14-year-old group. The CQ concentrations in blood on day 7 differed in patients over and under 
15 years (p = 0.008). A negative correlation was found between the real and theoretical dose (difference in dose) and 
the age in years (R2 = 0.529, p = 0.001). A negative correlation was also found between the difference in dose (mg) 
and CQ concentrations on day 7 (ng/ml) (r = −0.337, p = 0.001). Children under 15 years were found to have a higher 
rate of therapeutic failure than those over 15 (28 vs 4.2 %, respectively) (Kaplan–Meier p = 0.005).
Conclusions: A CQ dose of 25 mg/kg for the treatment of P. vivax malaria may be too low in children as demon-
strated by the reduction in CQ concentrations in blood at day 7 of follow-up. This under-dosage is probably associ-
ated with the higher rate of therapeutic failure found in children under 15 years (28 vs 4.3 %). These results suggest 
the need to review the paediatric doses of CQ currently used.
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Background
Vivax malaria continues to be an important health prob-
lem worldwide. It is estimated that this parasite caused 
13.8 million cases throughout the world in 2015 and con-
tributed to almost half of the cases of malaria reported 
outside of Africa. In South America, Plasmodium vivax 
causes 70 % of the total number of cases of malaria [1]. 
Despite the progressive resistance of Plasmodium falci-
parum to chloroquine (CQ) [2, 3], this drug continues to 
be the medication of choice in the treatment of malaria 
by P. vivax and special cases of malaria [4].
Recognition of the value of CQ occurred late, and this 
medication was not used until 1946 [5] after having been 
re-evaluated by the armed forces of the United States 
for its use against vivax malaria and later for falciparum 
malaria. The initial studies were carried out in military 
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personnel infected with P. vivax at a dose of 1.5  g dur-
ing four days [6]. The dose recommended by the World 
Health Organization (WHO) continues to be 25 mg/kg of 
body weight (BW), divided into three daily doses (1.5 g in 
patients of 60 kg) independently of the age of the patient 
[7].
CQ is completely absorbed through the gastrointes-
tinal tract and its maximum concentration is achieved 
1–3 h after oral ingestion, with 60 % of the drug binding 
to plasma proteins [8]. After the ingestion of a single oral 
dose CQ concentrations in whole blood are approximately 
tenfold greater than those in plasma. Following absorp-
tion, CQ is distributed throughout the body and accu-
mulates in the organs, especially the liver, lungs, spleen 
and kidneys [9]. The CQ distribution volume (DV) is very 
large (>200  l/kg), and it rapidly de-alkyates through the 
cytochrome P450 (CYP) enzymes into pharmacologically 
active desethylchloroquine (DCQ) and bisdesethylchloro-
quine. The mean half-life of the drug is from 35 to 40 days 
after ingestion [10]. The minimum effective concentration 
(MEC) of the drug in whole blood is 75–150 ng/ml, and, 
from the most conservative point of view, a CQ + DCQ 
concentration  >100  ng/ml in the presence of parasite 
growth is considered as resistance [11–13].
Breastfeeding infants and children under many changes 
along their development in regard to the absorption, dis-
tribution, metabolism and excretion of drugs, presenting 
important pharmacokinetic and pharmacodynamic dif-
ferences compared to adults [14, 15]. Indeed, these physi-
ological factors may influence the availability of drugs 
in the organism particularly with respect to body com-
position as well as extracellular and total body water, fat 
distribution and muscle mass [16]. Therefore, it has been 
recommended that drugs should be administered to chil-
dren according to their body surface area (BSA) [17, 18].
This wide variation in systemic exposure to drug con-
centrations has a significant effect on the effective drug 
concentrations achieved within the body. Suboptimal or 
low CQ concentrations in blood increase the risk of ther-
apeutic failure and the appearance and spread of resistant 
strains of Plasmodium [19–23].
In many studies on the therapeutic efficacy of CQ the 
rates of therapeutic failure and drug resistance were 
greater in children than in adults [24–28]. However, no 
evidence has shown that therapeutic failure in these cases 
is caused by suboptimal doses of CQ.
On the other hand, the lack of acquired immunity in 
children affects the spread of resistance to anti-malarial 
drugs [29], although this seems to be more related to 
infants [30]. In this respect recent reports have shown 
that paediatric doses of anti-malarial drugs should be re-
evaluated [31, 32].
The aim of this study was to evaluate whether the 
standard CQ dose of 25  mg/kg achieves the same CQ 
concentrations in blood of children and adults diagnosed 
with vivax malaria.
Methods
This study is a secondary analysis of the data of a clini-
cal trial on the therapeutic response of CQ in infection 
by P. vivax [33]. The analysis was carried out from May 
to November 2011 in the Amazonic area of Riberalta-
Bolivia, which has a medium high level of endemicity 
[34].
The inclusion criteria were: patients over 5  years of 
age diagnosed with mono parasitaemia by P. vivax, with 
a parasite density of asexual forms of 250–100,000 para-
sites/µl. The exclusion criteria were: pregnancy, signs and 
symptoms of severe malaria, history of allergy to anti-
malarial drugs, concomitant severe or chronic diseases 
such as tuberculosis or HIV/AIDS, and previous treat-
ment with other anti-malarial drugs.
All the patients were given scored tablets of CQ (Lote 
FCV 002A, Macleods Pharmaceuticals Ltd., India) at a 
dose of 25 mg/kg, divided into three daily doses: 10 mg/
kg on days 1 and 2 and 5 mg/kg on day 3. Patients pre-
senting vomiting half-an-hour after drug administration 
were given a new treatment cycle with the same dose, and 
patients with two new vomiting episodes were excluded 
from the study. Drug administration was strictly super-
vised by the study personnel, and dosing strategies based 
on age bands were not used.
The patients included in the study were followed over 
28 days with 5 clinical and laboratory evaluations accord-
ing to WHO guidelines for the assessment of therapeutic 
efficacy [13]. Data regarding the height, weight and BSA 
of all the patients were collected at admission. CQ and 
DCQ concentrations in whole blood were determined 
using high performance liquid chromatography (HPLC) 
at days 7 and 28 of follow-up. At day 28 of follow up all 
the patients were given oral primaquine (PQ) 0.5 mg/kg 
during 7 days according to the treatment schedule of the 
malaria program of Bolivia. Patients presenting therapeu-
tic failure or found to have mixed malaria were treated 
with an alternative schedule and excluded from the study.
Statistical analysis
The BSA was calculated using the Boyd formula 
(m2)  =  0.0003207  ×  height (cm) 0.3  ×  weight (g) 
0.7285 – [0.0188 × log (weight)] [35], and the dose of CQ 
in mg/m2 according to BSA was calculated using the for-
mula (BSA/1.73) × 1500 (adult dose) [17]. These varia-
bles were compared with CQ blood concentrations at day 
7 of follow up [36].
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Table 1 Characteristics: weight, BSA, CQ real-dose, CQ theoretical dose, and blood concentrations of CQ on day 7 of fol-
low-up in each group
CQ chloroquine, DCQ desethylchloroquine, SD standard deviation
a BSA in m2 = body surface area calculated using the Boyd formula
BSA (m2) = 0.0003207 × height (cm) 0.3 × weight (g) 0.7285 – [0.0188 × log (weight)]
b CQ real dose: CQ taken in mg/kg/weight
c CQ theoretical dose: CQ dose according to: (BSA/1.73)*1500 (adult dose)
d CQD7: CQ + DCQ on day 7 of follow-up




Weight (kg) BSAa (m2) CQ real doseb (mg) CQ theoretical  
dosec (m2)
CQD7d (ng/ml)
5–9 10 21.15 (SD 5.02) 0.83 (SD 0.13) 536.50 (SD 120.69) 717.71 (SD 112.48) 235.47 (SD 69.92)
10–14 14 42.92 (SD 9.02) 1.33 (SD 0.18) 1085.50 (SD 231.58) 1156.80 (SD 156.32) 308.20 (SD 89.69)
15–24 36 61.42 (SD 9.48) 1.68 (SD 0.15) 1542.81 (SD 239.85) 1458.84 (SD 133.87) 342.72 (SD 165.28)
25–34 14 62.12 (SD 12.60) 1.68 (SD 0.20) 1562.29 (SD 322.06) 1460.28 (SD 174.16) 455.35 (SD 137.86)
35–44 11 71.32 (SD 12.94) 1.83 (SD 0.19) 1782.82 (SD 323.69) 1589.72 (SD 162.42) 395.02 (SD 199.02)
45–54 6 64.67 (SD 8.74) 1.74 (SD 0.13) 1604.08 (SD 238.12) 1510.06 (SD 115.54) 384.57 (SD 51.47)
55–65 4 69.75 (SD 13.60) 1.80 (SD 0.21) 1745.00 (SD 342.08) 1564.96 (SD 183.79) 391.20 (SD 94.90)
Fig. 1 Description of chloroquine (mg) taken in mg/kg (real dose) and dose calculated as mg/m2 body surface area (BSA) (theoretical dose) by age 
group
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The statistical package SPSS® 21 (Chicago, IL, USA) 
was used to describe and express the variables studied. 
The normality of the quantitative variables and the resid-
ual values of the regression models were evaluated using 
a QQ-plot. Associations among variables were analysed 
by comparison of means using the Chi square or Fisher’s 
exact test and adjusting the linear or curvilinear regres-
sions. Kaplan–Meier analysis was used to estimate the 
rate of therapeutic failure. Estimations were made using a 
95 % confidence interval (CI), and all contrasts of hypoth-
esis were evaluated with an alpha risk of 5 %.
Results
A total of 96 patients diagnosed with P.vivax malaria 
were administered CQ at 25  mg/kg and CQ  +  DCQ 
concentrations in blood were assessed at day 7 of follow 
up. The details of the therapeutic evaluation have been 
described elsewhere [33]. One patient was excluded for 
having atypical height and weight values.
Table 1 shows the characteristics of the patients in each 
group including: weight, BSA, CQ dose in mg/kg (real 
dose), CQ dose calculated in mg/m2 of BSA (theoretical 
dose), and CQ + DCQ concentrations in blood on day 7 
of follow up (CQD7).
Figure  1 shows the description of the real and the 
theoretical CQ dose (mg) by age group. Statistically sig-
nificant differences were found between the two doses 
(p =  0.001). In the age groups of 5–9 and 10–14  years 
the real CQ dose was lower than the theoretical dose, 
being −181.206 mg (CI 95 % −195.39; −167.02 mg) and 
−71.30 mg (CI 95 % −118.61; −23.99 mg), respectively.
In contrast, the real CQ dose in patients over 15 years 
of age was greater than the theoretical CQ dose, with the 
difference between the two doses being 114.91  mg (CI 
95 % 82.64; 147.16 mg).
On analysing the variable “Difference in dose” defined 
as the difference between the real and theoretical dose, 
it was found that the younger the study population the 
larger the difference. Figure  2 shows a logistic model 
of the relationship of the difference in mg of the two 
doses and the age (R2 =  0.529, p =  0.001). The differ-
ence between the two doses was negative in patients 
under 15 years of age and could be interpreted as under 
dosing of CQ compared to the theoretical dose, while 
the difference was equal to or positive in patients over 
15 years.
Figure  3 describes the CQ concentrations on day 7 
(CQD7) by age group. These concentrations were found 
Fig. 2 CQD7 (ng/ml) description and analysis by age group. *CQD7 (ng/ml): CQ + DCQ on day 7 of follow up
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to be lower in children under 15 years of age compared to 
those over this age, with a mean difference of −101.40 ng/
ml (p = 0.008). Indeed, the difference was even greater in 
the group from 5–9 years of age compared to those over 
the age of 15, being −143.831 ng/ml (p = 0.033).
In relation to the difference between the real and the-
oretical dose of CQ, it was observed that the lower the 
real dose the lower the CQD7 values and the greater 
the difference with the theoretical dose. That is, a nega-
tive correlation was found between the difference of the 
dose (mg) and the CQD7 (ng/ml) (r = −0.337, p = 0.001) 
(Fig. 4).
On the other hand, of the 95 patients who fulfilled the 
criteria of normality, nine presented therapeutic fail-
ure: 1 on day 7, 2 on day 21 and 6 on day 28 of follow 
up. The mean age of the patients with therapeutic failure 
was 14.78 years and that of patients who were cured was 
25.20 years (p = 0.03).
On analysing therapeutic failure in relation to age 
group, the rate of therapeutic failure was found to 28 % 
in the groups younger than 15 and 4.2  % in the group 
greater than or equal to 15  years of age (Kaplan–Meier 
p = 0.005).
Discussion
The real and theoretical doses of CQ are different 
and vary with age (p  =  0.001). The greatest difference 
was found in the 5–9  year age group followed by the 
10–14-year-old group. On average these groups were 
administered −181.20 and −71.30  mg, respectively of 
Fig. 3 Correlation between the different doses of chloroquine (mg) and patient age (years). *Difference in doses (mg): difference between dose 
taken in mg/kg/weight and that calculated as mg/m2 of body surface area (BSA)
Page 6 of 8Añez et al. Malar J  (2016) 15:371 
CQ. To the contrary, patients over 15  years of age are 
prescribed more than they actually need with 114.91 mg. 
The relationship between the difference of the two doses 
and the age was adjusted in a logarithmic model and 
showed that the younger the age of the individual treated 
the lower the quantity of CQ prescribed.
With the dose of 25 mg/kg of body weight at diagno-
sis of P. vivax malaria, CQ concentrations in blood on 
day 7 of follow up were also lower in the youngest age 
group. The 5–9 years of age group was given an average 
of 143.831 mg/ml less than patients older than 15 years. 
These results are similar to those reported by Ringwald 
et  al. [37] who suggested that this could be due to an 
accelerated elimination of the drug in children.
Using doses of 25 and 50  mg/kg of CQ in children 
under 15 years of age with P. falciparum malaria, Ursing 
et  al. [32] also found that the younger the patients the 
lower the CQ concentrations at day 7.
Some authors have described the need to take into 
account that the renal and liver function, metabolic rate, 
total body and extracellular water, body fat distribution 
and muscle mass are different in children compared to 
adults [14, 16, 38]. This could probably explain the dif-
ferences associated with drug absorption, distribution, 
metabolism and excretion in children which lead to 
altered pharmacokinetics and may be the reason for the 
low CQ concentrations observed on day 7.
Previous studies using allometric scaling models have 
shown that the cause of the lowest CQ concentrations 
is probably due to under dosing [39, 40]. In this study it 
was also observed that the lower the age the greater the 
difference of the real and theoretical doses. A negative 
correlation was also found between the real and the theo-
retical dose of CQ calculated and age, and it was shown 
that the greater the difference in the dose the lower the 
CQ concentrations in blood on day 7 of follow up, sug-
gesting under dosing of CQ in children.
The association of the low level of CQ on day 7 found in 
children under 15 years and the rate of therapeutic failure 
of 28 % in this same group versus 4.2 % in subjects over 
15 years may help to interpret these results as suboptimal 
dosage of CQ in children under 15 years of age.
Fig. 4 Correlation between the different doses of chloroquine (mg) and chloroquine blood concentrations (ng/ml). *CQD7 (ng/ml): CQ + DCQ on 
day 7 of follow up. **Difference in doses (mg): difference between dose taken in mg/kg/weight and that calculated as mg/m2 of body surface area 
(BSA)
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These findings suggest the need to consider adjusting 
the paediatric doses of CQ. Some authors recommend the 
dose be increased between 35 and 50 mg/kg in children in 
order to achieve the same CQ concentrations on day 7 of 
follow up as those of adults [32, 40]. Indeed, several stud-
ies have shown that doses of up to 50 mg/kg of CQ can be 
given to children less than 15 years of age with the same 
adverse effects as those of a dose of 25 mg/kg [39, 41, 42].
Conclusion
The standard dose of CQ of 25  mg/kg in the treatment 
of P. vivax malaria may be suboptimal in children under 
15  years of age. This under-dosage may be related to a 
reduction in CQ concentrations found in blood on day 7 
of follow up, with younger children showing greater reduc-
tions. Indeed, the rate of therapeutic failure in children 
under 15 is greater than that in patients over this age prob-
ably due to this insufficient CQ doses in these patients.
Since suboptimal drug concentrations increase the risk 
of therapeutic failure and/or drug resistance, paediatric 
doses of CQ for the treatment of P. vivax malaria should 
be re-evaluated for each age group [23].
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